ArticlePatient preference and adherence2018
Affordability of essential medicine prices in Malaysia's private health sector.
Article in Patient preference and adherence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Evaluating factors associated with pharmaceutical price variation, dispersion and higher-tier pricing in Malaysia's public segmented procurement system: exploring market competition.Journal of pharmaceutical policy and practice · 2026Article
- Access to essential medicines used in the management of noncommunicable diseases in Southern Ethiopia: Analysis using WHO/HAI methodology.SAGE open medicine · 2024Article
- Factors affecting the availability of tracer health commodities in public facilities at Tana River County, Kenya.Journal of pharmaceutical policy and practice · 2023Article
- "What's up with price controls?" Stakeholders' views on the regulation of pharmaceutical pricing in Malaysia.PloS one · 2023Article
- The availability of priority medicines for children under 5 years in eThekwini, South Africa.Journal of pharmaceutical policy and practice · 2022Article
- Availability, pricing and affordability of essential medicines in Eastern Ethiopia: a comprehensive analysis using WHO/HAI methodology.Journal of pharmaceutical policy and practice · 2021Article
- Consumers' Knowledge, Attitudes, and Practices Toward Medicine Price Transparency at Private Healthcare Setting in Malaysia.Frontiers in public health · 2021Article
- Availability of Essential Medicines in a Country in Conflict: A Quantitative Insight from Yemen.International journal of environmental research and public health · 2020Article
- Multi stakeholders of health and industries perspectives on medicine price transparency initiative in private health care settings in Malaysia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future.Frontiers in public health · 2020Article
- Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.International journal of environmental research and public health · 2019Article
- Measuring Availability, Prices and Affordability of Ischaemic Heart Disease Medicines in Bangi, Selangor, Malaysia.The Malaysian journal of medical sciences : MJMS · 2019Article
- Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia's private healthcare sector.Journal of pharmaceutical policy and practice · 2019Article
- Hits and misses of Bangladesh National Health Policy 2011.Journal of pharmacy & bioallied sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lack of price control in Malaysia has led to increased market competition, resulting in high medicine prices, notably in the private sector. This largely affects patients' out-of-pocket expenses in the private sector. Although generic medicines are preferred due to affordability, the prices are still notably high.
methodsThis study compares innovator and generic medicine prices to estimate treatment affordability in the private sector. Private hospitals and community retail pharmacies were examined from 2011 to 2015. Data were collected on the basis of recommendations by the World Health Organization's Health Action International.
resultsThe markup of generic medicines was significantly higher than that of innovator medicines during the study period (
conclusionThere is a need for policies to control national drug prices, to ensure medicine prices are monitored. This can help keep out-of-pocket expenses, especially in middle-income countries such as Malaysia, at a minimal in the private sector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.